GABRIELLI, ARMANDO
 Distribuzione geografica
Continente #
NA - Nord America 237
EU - Europa 80
AS - Asia 27
Continente sconosciuto - Info sul continente non disponibili 1
Totale 345
Nazione #
US - Stati Uniti d'America 237
SE - Svezia 38
CN - Cina 24
IT - Italia 14
GB - Regno Unito 9
DE - Germania 8
RU - Federazione Russa 4
FI - Finlandia 3
ES - Italia 1
EU - Europa 1
FR - Francia 1
IE - Irlanda 1
IR - Iran 1
MD - Moldavia 1
MY - Malesia 1
TR - Turchia 1
Totale 345
Città #
Chandler 49
Nyköping 23
Fairfield 22
Woodbridge 18
Ashburn 15
Ann Arbor 14
Houston 10
Seattle 10
Beijing 9
Cambridge 8
New York 7
Roxbury 7
Wilmington 7
Lawrence 6
Brooklyn 4
Des Moines 4
Bari 3
Dearborn 3
Hefei 3
Jacksonville 3
Monza 3
Boardman 2
Hebei 2
Inglewood 2
Milan 2
Nanjing 2
Princeton 2
San Diego 2
Tianjin 2
Ardabil 1
Augusta 1
Chicago 1
Chisinau 1
Civitanova Marche 1
Dublin 1
Helsinki 1
Indiana 1
Jiaxing 1
Kuala Lumpur 1
Lanzhou 1
Leawood 1
Los Angeles 1
Madrid 1
Monmouth Junction 1
Nanchang 1
Paris 1
Redwood City 1
Rome 1
San Mateo 1
Shenyang 1
Washington 1
Xian 1
Totale 267
Nome #
Validation of the classification criteria for cryoglobulinaemic vasculitis 101
null 63
Early disease and low baseline damage predict response to belimumab in patients with systemic lupus erythematosus 56
Cancrini, Caterina, et al. "Clinical features and follow-up in patients with 22q11. 2 deletion syndrome." The Journal of pediatrics 164.6 (2014): 1475-1480. 46
Risk of acute arterial and venous thromboembolic events in Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss syndrome) 30
Prevalence of peripheral artery disease by abnormal ankle-brachial index in atrial fibrillation: Implications for risk and therapy 24
Efficacy, Safety, and Predictor of Response to Belimumab in a Large Nationwide Cohort Study of Patients with Active Systemic Lupus Erythematosus. 23
null 20
Early administration of tofacitinib in COVID ‐19 pneumonitis: An open randomised controlled trial 4
Early and Late Response and Glucocorticoid-Sparing Effect of Belimumab in Patients with Systemic Lupus Erythematosus with Joint and Skin Manifestations: Results from the Belimumab in Real Life Setting Study—Joint and Skin (BeRLiSS-JS) 3
Totale 370
Categoria #
all - tutte 1.958
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.958


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201914 0 0 0 0 0 0 0 0 0 2 6 6
2019/202059 9 2 2 3 2 4 7 6 3 4 15 2
2020/202155 6 5 1 4 4 5 2 5 1 6 8 8
2021/202266 0 2 2 3 9 11 0 5 3 7 9 15
2022/2023104 15 19 6 7 16 9 3 10 12 1 6 0
2023/202430 0 6 4 5 2 9 1 2 0 1 0 0
Totale 370